Letter
Medicine, General & Internal
Shuvadeep Ganguly, Ajay Gogia
Summary: In the KEYNOTE-522 trial, the addition of Pembrolizumab to neoadjuvant chemotherapy improved pathological complete response rate in early triple-negative breast cancer patients and also improved event-free survival. However, this improvement was predominantly observed in patients who did not achieve a pathological complete response.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Oncology
Jiulong Ma, Fengjun Wang, Chen Chen, Jiahua Ji, Peng Huang, Dexian Wei, Yang Zhang, Liqun Ren
Summary: In this study, the altered expression levels of lncRNAs, circRNAs, and mRNAs after treatment with pirarubicin (THP) in triple-negative breast cancer (TNBC) cells were identified. A co-expression network and ceRNA network were constructed, and hub genes with clinical value and importance were screened. These findings provide insights into the molecular targets and mechanisms of THP treatment in TNBC, and the ceRNA networks can be potential targets for treatment and prognostic markers in TNBC patients.
Article
Oncology
Xiaopan Zou, Yan Liu, Jun Di, Wei Wei, Nobumoto Watanabe, Jiang Li, Xiaomeng Li
Summary: This study found that ZMIZ2 is upregulated in TNBC tissues and is associated with its poor prognosis. ZMIZ2 may promote TNBC progression by promoting the expression of its target genes and affecting the corresponding pathways. ZMIZ2 may serve as a promising target for future TNBC treatments.
CANCER CELL INTERNATIONAL
(2022)
Article
Medicine, General & Internal
J. Cortes, H. S. Rugo, D. W. Cescon, S-A Im, M. M. Yusof, C. Gallardo, O. Lipatov, C. H. Barrios, J. Perez-Garcia, H. Iwata, N. Masuda, M. Torregroza Otero, E. Gokmen, S. Loi, Z. Guo, X. Zhou, V Karantza, W. Pan, P. Schmid
Summary: The addition of pembrolizumab to chemotherapy significantly improves overall survival in patients with advanced triple-negative breast cancer whose tumors express PD-L1 with a CPS of 10 or more.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Oncology
Jose P. Leone, Noah Graham, Julieta Leone, Sara M. Tolaney, Bernardo A. Leone, Rachel A. Freedman, Michael J. Hassett, Carlos T. Vallejo, Eric P. Winer, Nancy U. Lin, Nabihah Tayob
Summary: This study developed a tool called "ESTIMATE-TN" to assess the risk of breast cancer-specific mortality (BCSM), non-BCSM, and all-cause mortality in non-metastatic triple-negative breast cancer (TNBC) patients. The tool allows input of patient and tumor characteristics and provides a nonparametric estimate of cumulative risks using Gray's subdistribution method.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Jintao Cao, Shuai Sun, Rui Min, Ran Li, Xingyu Fan, Yuexin Han, Zhenzhong Feng, Nan Li
Summary: The study aimed to identify potential gene therapy targets for triple-negative breast cancer (TNBC) by analyzing gene expression profiles and protein-protein interaction networks, highlighting the crucial role of CCNB2 in the development of TNBC. High expression of CCNB2 was associated with poor prognosis, indicating its potential as a prognostic biomarker for TNBC patients.
CANCER MANAGEMENT AND RESEARCH
(2021)
Article
Multidisciplinary Sciences
Chitra Thakur, Yiran Qiu, Qian Zhang, Nicholas J. Carruthers, Miaomiao Yu, Zhuoyue Bi, Yao Fu, Priya Wadgaonkar, Bandar Almutairy, Akimasa Seno, Paul M. Stemmer, Fei Chen
Summary: This report provides evidence of diminished expression of the mineral dust-induced gene (mdig) in human triple negative breast cancer (TNBC). The study demonstrates that mdig promotes the growth of primary tumors but inhibits metastasis of TNBC cells. The findings also suggest a potential role of mdig in regulating genes related to cell motility, invasion, and metastasis.
Article
Oncology
Yu-Tien Chang, Wen-Chiuan Tsai, Wei-Zhi Lin, Chia-Chao Wu, Jyh-Cherng Yu, Vincent S. Tseng, Guo-Shiou Liao, Je-Ming Hu, Huan-Ming Hsu, Yu-Jia Chang, Meng-Chiung Lin, Chi-Ming Chu, Chien-Yi Yang
Summary: This study analyzed the function and prognostic value of immunoglobulin lambda constant 2 (IGLC2) in triple-negative breast cancer (TNBC) patients. The results showed that low expression of IGLC2 was associated with unfavorable relapse-free survival (RFS) and distant metastasis-free survival (DMFS). High expression of IGLC2 was related to a favorable prognosis and immune response in TNBC patients.
FRONTIERS IN ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Xue Yang, Yunqing Yang, Xueke Qian, Xiaodong Xu, Pengwei Lv
Summary: LINC01559 is significantly upregulated in TNBC tissues and acts as a carcinogenic ceRNA by sponging miRNAs, resulting in the increased expression of oncogenes and promoting TNBC progression. Targeting LINC01559 may be a potential treatment for TNBC patients.
BIOMEDICAL JOURNAL
(2022)
Review
Oncology
Juan Zhang, Qi Tian, Mi Zhang, Hui Wang, Lei Wu, Jin Yang
Summary: Breast cancer is a common female cancer worldwide, with triple-negative breast cancer being one of the most dangerous subtypes with high mortality and relapse rates. Immunotherapy has become a promising and effective treatment, but not all patients are sensitive to it, highlighting the importance of selecting suitable candidates for immunotherapy. Recent discoveries in immune-related factors of TNBC offer insights into predicting prognosis and response to immunotherapy.
Article
Oncology
Xiang Cui, Deba Song, Xiaoxu Li
Summary: A study designed effective nomograms to predict survival in childbearing-age TNBC patients, including overall survival and breast cancer-specific survival. Validation results showed excellent agreement between predicted and actual survival data, enabling individualized risk estimation and risk-adapted treatment.
FRONTIERS IN ONCOLOGY
(2021)
Letter
Medicine, General & Internal
Ryan Sun, Lee-Jen Wei
Summary: This article discusses the clinical benefits of pembrolizumab combined with chemotherapy in patients with triple-negative breast cancer. The authors suggest that both hazard values and ratios should be considered when evaluating clinical benefits.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Review
Oncology
Marina K. Ibragimova, Matvey M. Tsyganov, Nikolai V. Litviakov
Summary: Breast cancer is a genetically heterogeneous disease with different molecular biological and clinical characteristics, impacting drug treatment and prognosis. Understanding the genetic phenotype of breast cancer allows for personalized treatment and prognostic prediction.
Editorial Material
Chemistry, Multidisciplinary
Alexandre de Nonneville, Pascal Finetti, Daniel Birnbaum, Emilie Mamessier, Francois Bertucci
Summary: This study demonstrates the critical role of WEE1 in triple negative breast cancer, its pejorative prognostic value, and its correlation with biomarkers of sensitivity to WEE1 inhibitors.
Article
Oncology
Qianxue Wu, Xin Tang, Wenming Zhu, Qing Li, Xiang Zhang, Hongyuan Li
Summary: This study identified OBFC2A as an independent poor prognostic marker for TNBC, associated with immune functions in breast cancer. OBFC2A may promote the proliferation and migration of breast cancer cells, and its inhibition can block the cell cycle and increase apoptosis.
FRONTIERS IN ONCOLOGY
(2021)